Evidence map›Paper›PMID 29440708›Full record

ArticleOncogene2018

Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt's lymphoma cells.

Justine Debernardi, Emilie Hollville, Marc Lipinski, Joëlle Wiels, Aude Robert

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. [Value of prediction models for prognosis prediction of colorectal cancer: an analysis based on TCPA database].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021
    Article
  11. Article
  12. Article
  13. Verotoxin Receptor-Based Pathology and Therapies.Frontiers in cellular and infection microbiology · 2020
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Justine DebernardiUMR 8126, CNRS, Univ Paris Sud, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94805, France.
Emilie HollvilleUMR 8126, CNRS, Univ Paris Sud, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94805, France.
Marc LipinskiUMR 8126, CNRS, Univ Paris Sud, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94805, France.
Joëlle WielsUMR 8126, CNRS, Univ Paris Sud, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94805, France. joelle.wiels@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-3313-2937
Aude RobertUMR 8126, CNRS, Univ Paris Sud, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94805, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The globotriaosylceramide Gb3 is a glycosphingolipid expressed on a subpopulation of germinal center B lymphocytes which has been recognized as the B cell differentiation antigen CD77. Among tumoral cell types, Gb3/CD77 is strongly expressed in Burkitt's lymphoma (BL) cells as well as other solid tumors including breast, testicular and ovarian carcinomas. One known ligand of Gb3/CD77 is Verotoxin-1 (VT-1), a Shiga toxin produced in specific E. coli strains. Previously, we have reported that in BL cells, VT-1 induces apoptosis via a caspase-dependent and mitochondria-dependent pathway. Yet, the respective roles of various apoptogenic factors remained to be deciphered. Here, this apoptotic pathway was found to require cleavage of the BID protein by caspase-8 as well as activation of two other apoptogenic proteins, BAK and BAX. Surprisingly however, t-BID, the truncated form of BID resulting from caspase-8 cleavage, played no role in the conformational changes of BAK and BAX. Rather, their activation occurred under the control of full length BID (FL-BID). Indeed, introducing a non-cleavable form of BID (BID-D59A) into BID-deficient BL cells restored BAK and BAX activation following VT-1 treatment. Still, t-BID was involved along with FL-BID in the BAK-dependent and BAX-dependent cytosolic release of CYT C and SMAC/DIABLO from the mitochondrial intermembrane space: FL-BID was found to control the homo-oligomerization of both BAK and BAX, likely contributing to the initial release of CYT C and SMAC/DIABLO, while t-BID was needed for their hetero-oligomerization and ensuing release amplification. Together, our results reveal a functional cooperation between BAK and BAX during VT-1-induced apoptosis and, unexpectedly, that activation of caspase-8 and production of t-BID were not mandatory for initiation of the cell death process.

Indexed as

Apoptosisbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinBH3 Interacting Domain Death Agonist ProteinBurkitt LymphomaCaspase 8HEK293 CellsHumansProtein DomainsProtein IsoformsShiga ToxinsSignal TransductionTumor Cells, CulturedBAK1 protein, humanBAX protein, humanbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinBH3 Interacting Domain Death Agonist ProteinBID protein, humanCaspase 8Protein IsoformsShiga Toxins

Identifiers

PMID29440708
PMCPMC5931984
OpenAlexW2794420547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.